{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Ehlers L"],"funding":["German Research Foundation (DFG)","Horizon Pharma plc.","Charité-Universitätsmedizin"],"pagination":["5049"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9104323"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["23(9)"],"pubmed_abstract":["Unspecific antibody binding takes a significant toll on researchers in the form of both the economic burden and the disappointed hopes of promising new therapeutic targets. Despite recent initiatives promoting antibody validation, a uniform approach addressing this issue has not yet been developed. Here, we demonstrate that the anti-glucocorticoid receptor (GR) antibody clone 5E4 predominantly targets two different proteins of approximately the same size, namely AMP deaminase 2 (AMPD2) and transcription intermediary factor 1-beta (TRIM28). This paper is intended to generate awareness of unspecific binding of well-established reagents and advocate the use of more rigorous verification methods to improve antibody quality in the future."],"journal":["International journal of molecular sciences"],"pubmed_title":["The Anti-Glucocorticoid Receptor Antibody Clone 5E4: Raising Awareness of Unspecific Antibody Binding."],"pmcid":["PMC9104323"],"funding_grant_id":["112517"],"pubmed_authors":["Ehlers L","Kirchner M","Strehl C","Buttgereit F","Mertins P","Gaber T"],"additional_accession":[]},"is_claimable":false,"name":"The Anti-Glucocorticoid Receptor Antibody Clone 5E4: Raising Awareness of Unspecific Antibody Binding.","description":"Unspecific antibody binding takes a significant toll on researchers in the form of both the economic burden and the disappointed hopes of promising new therapeutic targets. Despite recent initiatives promoting antibody validation, a uniform approach addressing this issue has not yet been developed. Here, we demonstrate that the anti-glucocorticoid receptor (GR) antibody clone 5E4 predominantly targets two different proteins of approximately the same size, namely AMP deaminase 2 (AMPD2) and transcription intermediary factor 1-beta (TRIM28). This paper is intended to generate awareness of unspecific binding of well-established reagents and advocate the use of more rigorous verification methods to improve antibody quality in the future.","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 May","modification":"2026-04-08T10:37:47.391Z","creation":"2024-11-09T18:55:26.859Z"},"accession":"S-EPMC9104323","cross_references":{"pubmed":["35563440"],"doi":["10.3390/ijms23095049"]}}